Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.00M | $2.67M | $1.67M | $1.01M | $310K | $245K | $2.55M | $25.2M | $22.3M | $0.00 |
| Revenue growth | — | -33.3% | -37.3% | -39.9% | -69.1% | -21.1% | 941.8% | 886.8% | -11.5% | -100.0% |
| Operating income | -$17.0M | -$12.9M | -$15.3M | -$7.73M | -$13.7M | -$20.9M | -$29.7M | -$24.1M | -$42.6M | -$108M |
| Operating margin | -424.6% | -482.4% | -917.0% | -769.5% | -4412.6% | -8549.9% | -1163.9% | -95.6% | -191.1% | — |
| Net income | -$18.8M | $2.43M | -$15.2M | -$7.64M | -$13.7M | -$20.0M | -$29.0M | -$22.3M | -$40.5M | -$105M |
| Net margin | -470.3% | 91.2% | -908.9% | -760.4% | -4401.9% | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
| EPS (diluted) | -$1.01 | $0.09 | -$0.52 | -$2.06 | -$0.88 | -$0.87 | -$1.18 | -$0.83 | -$1.15 | -$2.26 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.5M | -$14.2M | -$13.9M | -$6.82M | -$10.1M | -$16.8M | $4.92M | -$25.6M | -$40.0M | -$69.8M |
| Capital expenditures | $192K | $32.2K | $316K | $0.00 | $548K | $1.20M | $2.00M | $1.31M | $1.17M | $2.90M |
| Free cash flow | -$14.6M | -$14.3M | -$14.2M | -$6.82M | -$10.6M | -$18.0M | $2.92M | -$26.9M | -$41.2M | -$72.7M |
| Share buybacks | — | — | $0.00 | $193.00 | $0.00 | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.20M | $6.14M | $4.26M | $3.90M | $32.7M | $34.9M | $9.60M | $14.7M | $11.3M | $288M |
| Total assets | $18.7M | $16.3M | $9.25M | $11.1M | $34.6M | $41.3M | $50.1M | $58.7M | $170M | $356M |
| Total liabilities | $22.8M | $5.05M | $4.63M | $4.27M | $6.42M | $9.96M | $38.3M | $36.1M | $25.0M | $50.2M |
| Shareholders' equity | -$4.00M | $11.2M | $4.62M | $6.84M | $28.2M | $31.4M | $11.8M | $22.6M | $145M | $306M |
| Retained earnings | -$54.0M | -$51.5M | -$66.7M | -$74.4M | -$88.0M | -$108M | -$137M | -$159M | -$200M | -$305M |
| Shares (wtd avg diluted) | 18.6M | 26.8M | 2.94M | 3.71M | 15.6M | 23.1M | 24.6M | 26.8M | 35.2M | 46.5M |
Every figure is extracted from CAPRICOR THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.